Figure 1 (Anastrozole Fig1)
Anastrozole Tablet
Product Images NDC 63629-5269
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 63629-5269). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Anastrozole Fig2)
Figure 3 (Anastrozole Fig3)
Figure 4 (Anastrozole Fig4)
Figure 5 (Anastrozole Fig5)
This appears to be a clinical trial report, specifically related to treatments for breast cancer. The text indicates that a treatment named Anastrozole was being tested against a drug called Tamoxifen, but it is unclear if the trial was successful, as the phrase "NOT PROGRESSING" suggests that the treatment did not work as intended. However, without further context or information, it is difficult to draw any definite conclusions from this text.*
Figure 6 (Anastrozole Fig6)
Chemical Structure For Anastrozole (Anastrozole Str)
Label Image (Lbl636295269)
This is the package of Anastrozole 1mg tablets, 30 count, manufactured by Intas Pharmaceuticals Limited. Anastrozole is used to treat breast cancer in women after menopause. The tablets are round, white, and should be stored at room temperature. The package has the NDC number 6362952691 and an expiration date of MM/YY. Keep the medication tightly closed and out of reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
